A multicenter, randomized, double-blind Phase 2 Trial of Lenvatinib (E7080) in subjects with 131I-Refractory Differentiated Thyroid Cancer to evaluate whether an oral starting dose of 20 mg or 14 mg daily will provide comparable efficacy to a 24-mg starting dose, but have a better safety profile.